Budesonide inhalation - Orion

Drug Profile

Budesonide inhalation - Orion

Alternative Names: Easyhaler Budesonide

Latest Information Update: 06 Jan 2016

Price : $50

At a glance

  • Originator Orion
  • Developer Menarini; Orion
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2015 Health Canada upheld the Notice of Deficiency - Withdrawal letter regarding Budesonide inhalation
  • 21 Nov 2015 Budesonide inhalation licensed to Pediapharm in Canada (Pediapharm, Form 10-K, March 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top